Does NECITUMUMAB Cause Malignant neoplasm progression? 54 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 54 reports of Malignant neoplasm progression have been filed in association with NECITUMUMAB (Portrazza). This represents 14.7% of all adverse event reports for NECITUMUMAB.
54
Reports of Malignant neoplasm progression with NECITUMUMAB
14.7%
of all NECITUMUMAB reports
19
Deaths
16
Hospitalizations
How Dangerous Is Malignant neoplasm progression From NECITUMUMAB?
Of the 54 reports, 19 (35.2%) resulted in death, 16 (29.6%) required hospitalization, and 3 (5.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NECITUMUMAB. However, 54 reports have been filed with the FAERS database.
What Other Side Effects Does NECITUMUMAB Cause?
Platelet count decreased (68)
Rash (48)
Hypomagnesaemia (46)
Neutrophil count decreased (45)
Dermatitis acneiform (44)
Febrile neutropenia (30)
Decreased appetite (29)
Neutropenia (26)
Nausea (21)
Death (20)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which NECITUMUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
NECITUMUMAB vs NEDAPLATIN
NECITUMUMAB vs NEFAZODONE
NECITUMUMAB vs NEFOPAM
NECITUMUMAB vs NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE\NEISSERIA MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN ANTIG
NECITUMUMAB vs NELARABINE